TradeFlare's AI research teams analysed ALKS on 9 market nights between May 13, 2026 and August 6, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| August 6, 2026 | BUY | $49.61 | — / — | +2.2% | -3.1% | The current technical and fundamental picture for ALKS is mixed, warranting a cautious approach. |
| August 5, 2026 | BUY | $49.67 | — / — | +1.4% | -3.8% | Continued strong revenue growth from existing products. |
| August 4, 2026 | HOLD | $49.53 | — / — | -0.9% | -5.0% | The stock is currently at resistance with mixed technical signals and a bearish fundamental outlook, warranting a cautious approach. |
| August 3, 2026 | HOLD | $48.99 | — / — | -0.3% | -5.1% | The stock is not actionable at this time. |
| July 31, 2026 | BUY | $50.03 | — / — | +0.4% | -3.2% | Post-earnings drift (PEAD) signal due to a significant EPS beat. |
| July 30, 2026 | BUY | $48.34 | — / — | -3.3% | -2.3% | The current market regime and the stock's technical profile do not support a new entry. |
| July 29, 2026 | BUY | $50.50 | — / — | +2.6% | +1.7% | Strong revenue growth driven by key products like LUMRYZ and LYBALVI. |
| June 1, 2026 | BUY | $42.19 | $47.90 / $37.58 | +0.4% | +24.0% | The 52-week breakout suggests potential for sustained upward momentum over the coming weeks. |
| May 13, 2026 | BUY | $38.29 | $43.87 / $35.37 | -5.0% | +15.4% | The stock is near its 52-week high with strong fundamental and technical indicators, suggesting potential for continued upward momentum over a few weeks. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.